XML 49 R38.htm IDEA: XBRL DOCUMENT v3.25.3
COMMITMENTS AND CONTINGENCIES (Tables)
 9 Months Ended
Sep. 30, 2025
Commitments and Contingencies Disclosure [Abstract]  
Schedule of Contingent Consideration
A reconciliation of the opening balances to the closing balances of these Level 3 measurements for the nine months ended September 30, 2025 and September 30, 2024 is as follows (in thousands):
Nine Months Ended September 30, 2025Contingent Consideration Liability Related to Acquisition of:
Arkis (1)
Derma Sciences (2)
ACell (2)
Surgical Innovations Associates (SIA), Inc. (2)
Total
Balance as of January 1, 2025
$12,968 $2,686 $3 54,000 69,657 
Payment(5,000)— — (18,075)(23,075)
Change in fair value of contingent consideration liabilities (1,770)(2,349)— (10,525)(14,644)
Balance as of September 30, 2025
6,198 337 3 25,400 31,938 
Short-Term - Accrued expenses and other liabilities$— $— $3 $25,400 $25,403 
Long-Term - Other liabilities6,198 337 — — 6,535 
Total6,198 337 3 25,400 31,938 
Nine Months Ended September 30, 2024Contingent Consideration Liability Related to Acquisition of:
Arkis (1)
Derma Sciences (2)
ACell (2)
Surgical Innovations Associates (SIA), Inc. (2)
Total
Balance as of January 1, 2024
$15,755 $2,557 $300 $68,700 87,312 
Payment(12,400)(12,400)
Change in fair value of contingent consideration liabilities(3,019)137 — 3,100 218 
Balance as of September 30, 2024
$12,736 $2,694 $300 $59,400 75,130 
Short-Term - Accrued expenses and other liabilities$8,320 $— $— $19,600 $27,920 
Long-Term - Other liabilities4,416 2,694 300 39,800 47,210 
Total12,736 2,694 300 59,400 75,130 
(1) Location in financial statements: Research and development
(2) Location in financial statements: Selling, general and administrative